XOMA Corporation is a biotechnology company with a diverse portfolio of innovative therapeutic antibodies. The Company’s innovative product candidates are the result of its expertise in developing ground-breaking monoclonal antibodies, which have created new opportunities to potentially treat a wide range of endocrine diseases.
XOMA's scientific research produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. Two of the assets were developed through the XOMA Metabolic or XMet platform, which consists of separate classes of Selective Insulin Receptor Modulators (SIRMs) that could have a major impact on the treatment of metabolic disorders.
XOMA 358, XOMA's lead product candidate, is a is a fully human negative allosteric antibody that reduces insulin receptor activity. XOMA recently initiated a Phase 2 proof-of-concept (POC) study in patients with congenital hyperinsulinism (CHI) and initiated a Phase 2 POC study in another rare hyperinsulinemic hypoglycemic (low blood glucose caused by excessive insulin produced endogenously) indication, post-bariatric surgery (PBS) induced hyperinsulinism.
XOMA 129, a novel antibody fragment (Fab) from the XMetD program, designed as a potential treatment for severe acute hypoglycemia. Preclinical data was presented at the Endocrine Society Meeting (ENDO 2016) in April.
XOMA is located in Berkeley, California.
May 4, 2016
XOMA Reports First Quarter 2016 Operational Achievements and Financial Results
Apr 27, 2016
XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
View all »Events & Presentations
Mar 9, 2016 at 4:30 PM ET
Fourth Quarter 2015 Financial Results Conference Call
Mar 7, 2016 at 2:40 PM ET
Cowen and Company 36th Annual Health Care Conference